Anti-CTLA-4 nanobodies are a promising approach in cancer immunotherapy. CTLA-4 is an essential immune molecule that regulates T cell activation and cytokine production. Inhibiting CTLA-4 has shown effectiveness in cancer therapy. Nanobodies, derived from the variable domain of heavy-chain antibodies, are small, stable, and have high affinity for their targets. They offer advantages over conventional monoclonal antibodies, including better tissue penetration, lower toxicity, and improved stability. Nanobodies can be used to block immune checkpoints, enhancing anti-tumor immune responses. They are effective in targeting CTLA-4, which is expressed on activated T cells and regulatory T cells. Anti-CTLA-4 nanobodies can improve T cell activation, proliferation, and memory cell formation, leading to enhanced antitumor effects. They also have potential in targeting other immune checkpoints and modulating the tumor microenvironment. Nanobodies can be engineered to enhance their half-life and functionality, such as by fusing with Fc receptors. They are also used in combination with other therapies, including CAR-T cells and siRNA-based approaches, to improve cancer treatment outcomes. Despite their promise, challenges remain in producing modified nanobodies with Fc receptors and ensuring their efficacy in clinical settings. Overall, anti-CTLA-4 nanobodies represent a promising strategy for cancer immunotherapy due to their unique properties and potential for targeted treatment.Anti-CTLA-4 nanobodies are a promising approach in cancer immunotherapy. CTLA-4 is an essential immune molecule that regulates T cell activation and cytokine production. Inhibiting CTLA-4 has shown effectiveness in cancer therapy. Nanobodies, derived from the variable domain of heavy-chain antibodies, are small, stable, and have high affinity for their targets. They offer advantages over conventional monoclonal antibodies, including better tissue penetration, lower toxicity, and improved stability. Nanobodies can be used to block immune checkpoints, enhancing anti-tumor immune responses. They are effective in targeting CTLA-4, which is expressed on activated T cells and regulatory T cells. Anti-CTLA-4 nanobodies can improve T cell activation, proliferation, and memory cell formation, leading to enhanced antitumor effects. They also have potential in targeting other immune checkpoints and modulating the tumor microenvironment. Nanobodies can be engineered to enhance their half-life and functionality, such as by fusing with Fc receptors. They are also used in combination with other therapies, including CAR-T cells and siRNA-based approaches, to improve cancer treatment outcomes. Despite their promise, challenges remain in producing modified nanobodies with Fc receptors and ensuring their efficacy in clinical settings. Overall, anti-CTLA-4 nanobodies represent a promising strategy for cancer immunotherapy due to their unique properties and potential for targeted treatment.